{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:02:53Z","timestamp":1773993773024,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PECART-0207-2020"],"award-info":[{"award-number":["PECART-0207-2020"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>HER2 overexpression in breast cancer correlates with poor outcomes. The incorporation of Trastuzumab into the treatment regimen has notably improved patient prognoses. However, cardiotoxicity emerges in approximately 20% of patients treated with the drug. This study aims to investigate the association between the HER2 655 A\u2009&gt;\u2009G polymorphism, Trastuzumab-induced cardiotoxicity, and patient survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study involved 88 patients treated with Trastuzumab. Cardiotoxicity, defined as a reduction in left ventricular ejection fraction (LVEF) from baseline or the emergence of clinical signs of congestive heart failure, was identified during treatment follow-up. Genotyping of HER2 655 A\u2009&gt;\u2009G employed TaqMan SNP technology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Genotype frequencies of HER2\/neu 655 (53 AA, 32 AG, and 3 GG) were consistent with Hardy\u2013Weinberg equilibrium. No significant differences were observed in mean baseline LVEF between patients who developed cardiotoxicity and those who did not. Within these groups, neither AA nor AG genotypes showed an association with changes in mean baseline or reduced LVEF levels. Logistic regression analysis, adjusted for hormonal status and anthracycline treatment, revealed that AG genotype carriers face a significantly higher risk of cardiotoxicity compared to AA carriers (OR\u2009=\u20094.42; p\u2009=\u20090.037). No association was found between the HER2\/neu 655 A\u2009&gt;\u2009G polymorphism and disease-free or overall survival, regardless of whether the data was adjusted for stage or not.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>HER2 655 A\u2009&gt;\u2009G polymorphism is significantly linked to an increased risk of Trastuzumab-induced cardiotoxicity but does not correlate with variations in disease-free survival or overall survival rates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-024-03512-6","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T14:01:37Z","timestamp":1716300097000},"page":"2531-2540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HER2\/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-6615","authenticated-orcid":false,"given":"Isabel","family":"Blancas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-1123","authenticated-orcid":false,"given":"Marina","family":"Linares-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-5043","authenticated-orcid":false,"given":"Celia","family":"Mart\u00edn-Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-7865","authenticated-orcid":false,"given":"Celia","family":"G\u00f3mez-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7105-4060","authenticated-orcid":false,"given":"Fernando","family":"Rodr\u00edguez-Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"3512_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2741\/E765","volume":"8","author":"SR Sirkisoon","year":"2016","unstructured":"Sirkisoon SR, Carpenter RL, Rimkus T, Miller L, Metheny-Barlow L, Lo H-W. EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed). 2016;8:245\u201363. https:\/\/doi.org\/10.2741\/E765.","journal-title":"Front Biosci (Elite Ed)"},{"key":"3512_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.breast.2023.07.008","volume":"71","author":"W Chen","year":"2023","unstructured":"Chen W, Li F-X, Lu D-L, Jiang J, Li J. Differences between the efficacy of HER2(2+)\/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy. Breast. 2023;71:69\u201373. https:\/\/doi.org\/10.1016\/j.breast.2023.07.008.","journal-title":"Breast"},{"key":"3512_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.breast.2021.11.016","volume":"61","author":"C-H Chang","year":"2022","unstructured":"Chang C-H, Jung C-J, Huang Y-M, Chiao L, Chang Y-L, Hsieh S-C, et al. The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis - a case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up. Breast. 2022;61:35\u201342. https:\/\/doi.org\/10.1016\/j.breast.2021.11.016.","journal-title":"Breast"},{"key":"3512_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab \u2014 mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39\u201351. https:\/\/doi.org\/10.1056\/NEJMra043186.","journal-title":"N Engl J Med"},{"key":"3512_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273\u201383. https:\/\/doi.org\/10.1056\/NEJMoa0910383.","journal-title":"N Engl J Med"},{"key":"3512_CR6","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1093\/annonc\/mdq096","volume":"21","author":"RB Costa","year":"2010","unstructured":"Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010;21:2153\u201360. https:\/\/doi.org\/10.1093\/annonc\/mdq096.","journal-title":"Ann Oncol"},{"key":"3512_CR7","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S1470-2045(13)70384-X","volume":"14","author":"SE Jones","year":"2013","unstructured":"Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013;14:1121\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(13)70384-X.","journal-title":"Lancet Oncol"},{"key":"3512_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11523-011-0203-8","volume":"6","author":"S Di Cosimo","year":"2011","unstructured":"Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol. 2011;6:189\u201395. https:\/\/doi.org\/10.1007\/s11523-011-0203-8.","journal-title":"Target Oncol"},{"key":"3512_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.yexcr.2008.10.008","volume":"315","author":"KR Schmitz","year":"2009","unstructured":"Schmitz KR, Ferguson KM. Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res. 2009;315:659\u201370. https:\/\/doi.org\/10.1016\/j.yexcr.2008.10.008.","journal-title":"Exp Cell Res"},{"key":"3512_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.breast.2022.06.007","volume":"65","author":"AT Vuger","year":"2022","unstructured":"Vuger AT, Tiscoski K, Apolinario T, Cardoso F. Anthracyclines in the treatment of early breast cancer friend or foe? Breast. 2022;65:67\u201376. https:\/\/doi.org\/10.1016\/j.breast.2022.06.007.","journal-title":"Breast"},{"key":"3512_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215\u201321. https:\/\/doi.org\/10.1200\/JCO.2002.20.5.1215.","journal-title":"J Clin Oncol"},{"key":"3512_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000073","volume":"1","author":"NF Pond\u00e9","year":"2016","unstructured":"Pond\u00e9 NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open. 2016;1: e000073. https:\/\/doi.org\/10.1136\/esmoopen-2016-000073.","journal-title":"ESMO Open"},{"key":"3512_CR13","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","volume":"25","author":"TM Suter","year":"2007","unstructured":"Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859\u201365. https:\/\/doi.org\/10.1200\/JCO.2006.09.1611.","journal-title":"J Clin Oncol"},{"key":"3512_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.018393","volume":"10","author":"H Abdel-Qadir","year":"2021","unstructured":"Abdel-Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo-Arg\u00fcelles O, Amir E, et al. Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: a propensity score-matched cohort study. J Am Heart Assoc. 2021;10: e018393. https:\/\/doi.org\/10.1161\/JAHA.119.018393.","journal-title":"J Am Heart Assoc"},{"key":"3512_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yjmcc.2006.04.007","volume":"41","author":"Y Kuramochi","year":"2006","unstructured":"Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src\/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol. 2006;41:228\u201335. https:\/\/doi.org\/10.1016\/j.yjmcc.2006.04.007.","journal-title":"J Mol Cell Cardiol"},{"key":"3512_CR16","first-page":"70","volume":"16","author":"M Zeglinski","year":"2011","unstructured":"Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: a \u2018dual-hit.\u2019 Exp Clin Cardiol. 2011;16:70\u20134.","journal-title":"Exp Clin Cardiol"},{"key":"3512_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.breast.2020.09.001","volume":"54","author":"I Blancas","year":"2020","unstructured":"Blancas I, Mart\u00edn-P\u00e9rez FJ, Garrido JM, Rodr\u00edguez-Serrano F. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Breast. 2020;54:106\u201313. https:\/\/doi.org\/10.1016\/j.breast.2020.09.001.","journal-title":"Breast"},{"key":"3512_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/echo.13743","volume":"35","author":"S \u00c7etin","year":"2018","unstructured":"\u00c7etin S, Babao\u011flu K, Ba\u015far EZ, Deveci M, \u00c7orap\u00e7\u0131o\u011flu F. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography. Echocardiography. 2018;35:234\u201340. https:\/\/doi.org\/10.1111\/echo.13743.","journal-title":"Echocardiography"},{"key":"3512_CR19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.echo.2008.10.008","volume":"21","author":"BW Eidem","year":"2008","unstructured":"Eidem BW. Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough. J Am Soc Echocardiogr. 2008;21:1290\u20132. https:\/\/doi.org\/10.1016\/j.echo.2008.10.008.","journal-title":"J Am Soc Echocardiogr"},{"key":"3512_CR20","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/JCO.2007.14.8742","volume":"26","author":"MS Ewer","year":"2008","unstructured":"Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2008;26:1201\u20133. https:\/\/doi.org\/10.1200\/JCO.2007.14.8742.","journal-title":"J Clin Oncol"},{"key":"3512_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/eurheartj\/ehi666","volume":"27","author":"LD Jacobs","year":"2006","unstructured":"Jacobs LD, Salgo IS, Goonewardena S, Weinert L, Coon P, Bardo D, et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J. 2006;27:460\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehi666.","journal-title":"Eur Heart J"},{"key":"3512_CR22","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.3390\/cancers14194665","volume":"14","author":"R Altena","year":"2022","unstructured":"Altena R, Bajalica-Lagercrantz S, Papakonstantinou A. Pharmacogenomics for prediction of cardiovascular toxicity: landscape of emerging data in breast cancer therapies. Cancers (Basel). 2022;14:4665. https:\/\/doi.org\/10.3390\/cancers14194665.","journal-title":"Cancers (Basel)"},{"key":"3512_CR23","doi-asserted-by":"publisher","first-page":"15937","DOI":"10.1073\/pnas.252640799","volume":"99","author":"SJ Fleishman","year":"2002","unstructured":"Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A. 2002;99:15937\u201340. https:\/\/doi.org\/10.1073\/pnas.252640799.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3512_CR24","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1093\/nar\/19.19.5452-a","volume":"19","author":"J Papewalis","year":"1991","unstructured":"Papewalis J, Nikitin AYu, Rajewsky MF. G to A polymorphism at amino acid codon 655 of the human erbB-2\/HER2 gene. Nucleic Acids Res. 1991;19:5452.","journal-title":"Nucleic Acids Res"},{"key":"3512_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/jso.23386","volume":"108","author":"H Wang","year":"2013","unstructured":"Wang H, Liu L, Lang Z, Guo S, Gong H, Guan H, et al. Polymorphisms of ERBB2 and breast cancer risk: a meta-analysis of 26 studies involving 35,088 subjects. J Sur Oncol. 2013;108:337\u201341. https:\/\/doi.org\/10.1002\/jso.23386.","journal-title":"J Sur Oncol"},{"key":"3512_CR26","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/FPC.0000000000000149","volume":"25","author":"C G\u00f3mez Pe\u00f1a","year":"2015","unstructured":"G\u00f3mez Pe\u00f1a C, D\u00e1vila-Fajardo CL, Mart\u00ednez-Gonz\u00e1lez LJ, Carmona-S\u00e1ez P, Soto Pino MJ, S\u00e1nchez Ramos J, et al. Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis. Pharmacogenet Genom. 2015;25:388\u201393. https:\/\/doi.org\/10.1097\/FPC.0000000000000149.","journal-title":"Pharmacogenet Genom"},{"key":"3512_CR27","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/annonc\/mdm181","volume":"18","author":"S Beauclair","year":"2007","unstructured":"Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol. 2007;18:1335\u201341. https:\/\/doi.org\/10.1093\/annonc\/mdm181.","journal-title":"Ann Oncol"},{"key":"3512_CR28","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.3390\/cancers15133290","volume":"15","author":"A Alexandraki","year":"2023","unstructured":"Alexandraki A, Papageorgiou E, Zacharia M, Keramida K, Papakonstantinou A, Cipolla CM, et al. New Insights in the era of clinical biomarkers as potential predictors of systemic therapy-induced cardiotoxicity in women with breast cancer: a systematic review. Cancers (Basel). 2023;15:3290. https:\/\/doi.org\/10.3390\/cancers15133290.","journal-title":"Cancers (Basel)"},{"key":"3512_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.15420\/cfr.2018.25.1","volume":"5","author":"M Nicol","year":"2019","unstructured":"Nicol M, Baudet M, Cohen-Solal A. Subclinical left ventricular dysfunction during chemotherapy. Card Fail Rev. 2019;5:31\u20136. https:\/\/doi.org\/10.15420\/cfr.2018.25.1.","journal-title":"Card Fail Rev"},{"key":"3512_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s100380200019","volume":"47","author":"M-M Ameyaw","year":"2002","unstructured":"Ameyaw M-M, Tayeb M, Thornton N, Folayan G, Tariq M, Mobarek A, et al. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet. 2002;47:172\u20135. https:\/\/doi.org\/10.1007\/s100380200019.","journal-title":"J Hum Genet"},{"key":"3512_CR31","first-page":"365","volume":"54","author":"E Papadopoulou","year":"2007","unstructured":"Papadopoulou E, Simopoulos K, Tripsianis G, Tentes I, Anagnostopoulos K, Sivridis E, et al. Allelic imbalance of HER-2 codon 655 polymorphism among different religious\/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma. 2007;54:365\u201373.","journal-title":"Neoplasma"},{"key":"3512_CR32","first-page":"2569","volume":"33","author":"J Lemieux","year":"2013","unstructured":"Lemieux J, Diorio C, C\u00f4t\u00e9 M-A, Provencher L, Barab\u00e9 F, Jacob S, et al. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res. 2013;33:2569\u201376.","journal-title":"Anticancer Res"},{"key":"3512_CR33","first-page":"286","volume":"13","author":"L Tan","year":"2020","unstructured":"Tan L, Su X, Li X, Li H, Hu B. Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin\/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy. Int J Clin Exp Pathol. 2020;13:286\u201394.","journal-title":"Int J Clin Exp Pathol"},{"key":"3512_CR34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s10549-013-2587-x","volume":"139","author":"L Roca","year":"2013","unstructured":"Roca L, Di\u00e9ras V, Roch\u00e9 H, Lappartient E, Kerbrat P, Cany L, et al. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat. 2013;139:789\u2013800. https:\/\/doi.org\/10.1007\/s10549-013-2587-x.","journal-title":"Breast Cancer Res Treat"},{"key":"3512_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/FPC.0000000000000302","volume":"27","author":"DJ Serie","year":"2017","unstructured":"Serie DJ, Crook JE, Necela BM, Dockter TJ, Wang X, Asmann YW, et al. Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet Genom. 2017;27:378. https:\/\/doi.org\/10.1097\/FPC.0000000000000302.","journal-title":"Pharmacogenet Genom"},{"key":"3512_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12885-015-1298-6","volume":"15","author":"SE Stanton","year":"2015","unstructured":"Stanton SE, Ward MM, Christos P, Sanford R, Lam C, Cobham MV, et al. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer. 2015;15:267. https:\/\/doi.org\/10.1186\/s12885-015-1298-6.","journal-title":"BMC Cancer"},{"key":"3512_CR37","doi-asserted-by":"publisher","first-page":"e687","DOI":"10.1016\/j.clbc.2017.11.012","volume":"18","author":"D Furrer","year":"2018","unstructured":"Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C. Association of tobacco use, alcohol consumption and HER2 polymorphisms with response to trastuzumab in HER2-positive breast cancer patients. Clin Breast Cancer. 2018;18:e687\u201394. https:\/\/doi.org\/10.1016\/j.clbc.2017.11.012.","journal-title":"Clin Breast Cancer"},{"key":"3512_CR38","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/annonc\/mdu111","volume":"25","author":"X Han","year":"2014","unstructured":"Han X, Diao L, Xu Y, Xue W, Ouyang T, Li J, et al. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer. Ann Oncol. 2014;25:1158\u201364. https:\/\/doi.org\/10.1093\/annonc\/mdu111.","journal-title":"Ann Oncol"},{"key":"3512_CR39","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/1078-0432.CCR-21-1762","volume":"28","author":"PF Peddi","year":"2022","unstructured":"Peddi PF, Fasching PA, Liu D, Quinaux E, Robert NJ, Valero V, et al. Genetic polymorphisms and correlation with treatment-induced cardiotoxicity and prognosis in patients with breast cancer. Clin Cancer Res. 2022;28:1854\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1762.","journal-title":"Clin Cancer Res"},{"key":"3512_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4901","volume":"351","author":"S Saadatmand","year":"2015","unstructured":"Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MMA. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients. BMJ. 2015;351: h4901. https:\/\/doi.org\/10.1136\/bmj.h4901.","journal-title":"BMJ"},{"key":"3512_CR41","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/ijc.11226","volume":"106","author":"M Sant","year":"2003","unstructured":"Sant M, Allemani C, Capocaccia R, Hakulinen T, Aareleid T, Coebergh JW, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003;106:416\u201322. https:\/\/doi.org\/10.1002\/ijc.11226.","journal-title":"Int J Cancer"},{"key":"3512_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/annonc\/mds330","volume":"24","author":"PE Goss","year":"2013","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol. 2013;24:355\u201361. https:\/\/doi.org\/10.1093\/annonc\/mds330.","journal-title":"Ann Oncol"},{"key":"3512_CR43","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3109\/02841869209083845","volume":"31","author":"S Aaltomaa","year":"1992","unstructured":"Aaltomaa S, Lipponen P, Eskelinen M. Demographic prognostic factors in breast cancer. Acta Oncol. 1992;31:635\u201340. https:\/\/doi.org\/10.3109\/02841869209083845.","journal-title":"Acta Oncol"},{"key":"3512_CR44","doi-asserted-by":"publisher","first-page":"14340","DOI":"10.1038\/s41598-021-93676-w","volume":"11","author":"H Abdel-Razeq","year":"2021","unstructured":"Abdel-Razeq H, Iweir S, Abdel-Razeq R, Rahman FA, Almasri H, Bater R, et al. Differences in clinicopathological characteristics, treatment, and survival outcomes between older and younger breast cancer patients. Sci Rep. 2021;11:14340. https:\/\/doi.org\/10.1038\/s41598-021-93676-w.","journal-title":"Sci Rep"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03512-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03512-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03512-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:09:23Z","timestamp":1726718963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03512-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3512"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03512-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Isabel Blancas received grants and support by Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed, written consent was obtained from all participants involved in the study. Additionally, the research received approval from the Provincial Ethical Committee of Granada, ensuring adherence to ethical standards in the conduct of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval, Human participants and\/or animals and Informed consent"}}]}}